Kangtai Biological shareholders approve governance revisions

Shenzhen Kangtai Biological Products Co., Ltd. held its third extraordinary general meeting of shareholders for 2025 on November 18, 2025. A total of 354 shareholders and proxies attended, representing 521,918,431 shares with voting rights, or 46.7280% of the company's total shares. The meeting, presided over by chairman Mr. Du Weimin, approved all proposed resolutions, including significant revisions to the company's articles of association and various governance policies.

The "Revision of the Articles of Association" was passed with 99.8239% of votes in favor, 0.1427% against, and 0.0334% abstaining. Resolutions to revise the "Rules of Procedure for Shareholder Meetings," "Rules of Procedure for Board Meetings," "Independent Director System," "External Guarantees Management System," "Related Party Transactions Decision-Making System," "Investment and Financing Management System," "Funds Raised Management System," "Accountant Selection System," "Prevention of Controlling Shareholders and Related Parties Occupying Company Funds System," and "Compensation Management System for Directors, Supervisors, and Senior Management Personnel" were also all approved by significant majorities, generally exceeding 99% of votes in favor.

The meeting ensured compliance with relevant laws and company regulations, with voting conducted through both on-site and online channels. The resolutions reflect an update to the company's internal governance framework.